Jazz Pharmaceuticals Reports Key Financial and Corporate Events
Ticker: JAZZ · Form: 8-K · Filed: Sep 6, 2024 · CIK: 1232524
| Field | Detail |
|---|---|
| Company | Jazz Pharmaceuticals PLC (JAZZ) |
| Form Type | 8-K |
| Filed Date | Sep 6, 2024 |
| Risk Level | medium |
| Pages | 11 |
| Reading Time | 13 min |
| Key Dollar Amounts | $0.0001, $1.0 billion, $150.0 million, $981.0 m, $500.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, debt, equity-sale
TL;DR
Jazz Pharma inked a new deal, took on debt, and sold some stock. Big moves happening.
AI Summary
On September 3, 2024, Jazz Pharmaceuticals plc entered into a material definitive agreement related to its financing. The company also reported on the creation of a direct financial obligation and unregistered sales of equity securities. This filing details significant financial and corporate events for Jazz Pharmaceuticals.
Why It Matters
This filing provides insight into Jazz Pharmaceuticals' financing activities and potential equity issuances, which could impact its financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements, financial obligations, and unregistered equity sales, which carry inherent financial and regulatory risks.
Key Players & Entities
- Jazz Pharmaceuticals plc (company) — Registrant
- September 3, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did Jazz Pharmaceuticals enter into?
The filing indicates Jazz Pharmaceuticals entered into a material definitive agreement related to its financing, but specific details of the agreement are not provided in the summary.
What are the key items reported in this 8-K filing?
The key items reported are the entry into a material definitive agreement, the creation of a direct financial obligation, and unregistered sales of equity securities.
When was the earliest event reported in this filing?
The earliest event reported was on September 3, 2024.
What is the company's jurisdiction of incorporation?
The company is incorporated in Ireland.
What is the SIC code for Jazz Pharmaceuticals?
The Standard Industrial Classification (SIC) code for Jazz Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 3,365 words · 13 min read · ~11 pages · Grade level 16.2 · Accepted 2024-09-06 16:09:31
Key Financial Figures
- $0.0001 — stered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Mark
- $1.0 billion — reviously announced private offering of $1.0 billion aggregate principal amount of its 3.125
- $150.0 million — option to purchase up to an additional $150.0 million aggregate principal amount of Notes, to
- $981.0 m — additional Notes, will be approximately $981.0 million, after deducting the Initial Purc
- $500.0 million — proceeds to prepay up to approximately $500.0 million aggregate principal amount of the term
- $109.32 — y share on September 3, 2024, which was $109.32 per ordinary share. The Company paid fo
- $1,000 — 0001 per share ("ordinary shares"), per $1,000 principal amount of the Notes, which is
- $153.05 — initial exchange price of approximately $153.05 per ordinary share. Upon exchange of th
- $125.0 million — ed with a principal amount in excess of $125.0 million (or its foreign currency equivalent at
Filing Documents
- d875709d8k.htm (8-K) — 53KB
- d875709dex41.htm (EX-4.1) — 708KB
- d875709dex991.htm (EX-99.1) — 13KB
- d875709dex992.htm (EX-99.2) — 16KB
- g875709dsp7.jpg (GRAPHIC) — 6KB
- 0001193125-24-215168.txt ( ) — 1088KB
- jazz-20240903.xsd (EX-101.SCH) — 3KB
- jazz-20240903_lab.xml (EX-101.LAB) — 18KB
- jazz-20240903_pre.xml (EX-101.PRE) — 11KB
- d875709d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, all statements related to the expected use of the net proceeds from the offering, including any prepayment of the term loans outstanding under the credit agreement and other statements that are not historical facts. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Do not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with market risks, trends and conditions. These and other risks and uncertainties relating to the Company and its business can be found under the caption "Risk Factors" and elsewhere in the Company's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as supplemented by its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as well as future filings and reports by the Company. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this Current Report on Form 8-K as a result of new information, future events or changes in its expectations. Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 4.1 Indenture, dated as of September 6, 2024 among Jazz Pharmaceuticals Public Limited Company, Jazz Investments I Limited and U.S. Bank Trust Company, National Association 4.2 Form of 3.125% Exchangeable Senior Note due 2030 (included in Exhibit 4.1) 99.1 Press Release dated September 3, 2024 99.2 Press Release dated September 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Neena Patil Name: Neena Patil Title: Executive Vice President and Chief Legal Officer Date: September 6, 2024